tiprankstipranks
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market

TScan Therapeutics (TCRX) Financial Statements

158 Followers

TScan Therapeutics Financial Overview

TScan Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.479; its P/E ratio is -4.56; TScan Therapeutics is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is $-0.28. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 566.00K$ 7.21M$ 3.89M$ 3.15M$ 6.80M
Gross Profit$ 566.00K$ 7.21M$ 3.89M$ 3.15M$ 6.80M
EBIT$ -29.18M$ -18.76M$ -22.02M$ -23.08M$ -22.74M
EBITDA$ -27.93M$ -17.48M--$ -21.24M
Net Income Common Stockholders$ -30.14M$ -19.61M$ -23.00M$ -24.05M$ -22.56M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 162.78M$ 192.04M$ 215.42M$ 208.84M$ 95.61M
Total Assets$ 240.83M$ 272.15M$ 291.38M$ 316.92M$ 173.58M
Total Debt$ 91.76M$ 92.43M$ 86.98M$ 87.74M$ 85.31M
Net Debt$ -71.02M$ -99.61M$ -128.44M$ -121.10M$ -10.30M
Total Liabilities$ 117.86M$ 121.28M$ 122.42M$ 126.32M$ 95.56M
Stockholders Equity$ 122.97M$ 150.87M$ 168.96M$ 190.61M$ 78.02M
Cash Flow-
Free Cash Flow$ -29.97M$ -24.23M--$ -24.43M
Operating Cash Flow$ -29.27M$ -23.77M$ 8.02M-$ -23.59M
Investing Cash Flow$ 36.16M$ 1.91M$ -61.41M-$ -838.00K
Financing Cash Flow$ 258.00K$ 19.00K$ -252.00K--
Currency in USD

TScan Therapeutics Earnings and Revenue History

TScan Therapeutics Debt to Assets

TScan Therapeutics Cash Flow

TScan Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis